Novateor Research Laboratories Limited , a company listed on the Bombay Stock Exchange (BSE: 542771), is seeking shareholder approval to diversify its business operations. The company has proposed amendments to its Memorandum of Association (MOA) to include new business activities in dental equipment trading and chemicals trading.

Proposed Business Expansion

Dental Equipment Trading

Novateor plans to enter the dental equipment market with a comprehensive approach. The proposed activities include:

• Importing, exporting, distributing, and dealing in dental equipment, instruments, devices, and consumables
• Handling digital and diagnostic tools for dental applications
• Acting as representatives or distributors for domestic and foreign manufacturers in the dental and allied healthcare products sector

Chemicals Trading

The company also aims to venture into the chemicals sector with the following activities:

• Trading, importing, exporting, and distributing various chemicals, paints, coatings, emulsions, varnishes, resins, adhesives, and solvents
• Formulating, blending, mixing, and packaging chemical products
• Providing painting, coating, waterproofing, and protective treatment services for industrial, commercial, and residential premises

Corporate Governance and Compliance

The proposed expansion requires restructuring the Objects clause of the company's MOA, subject to appropriate regulatory approvals. Novateor has taken steps to ensure compliance with regulatory requirements:

1. The company held its 14th Annual General Meeting (AGM) on September 30, where the proposed amendments were presented as a special resolution.

2. Mr. Anil Tilakraj Arora (DIN: 03469947) has been appointed as a Non-Executive Independent Director for a term of five years, effective September 3. Mr. Arora brings over 40 years of experience as a dental practitioner and entrepreneur, which aligns with the company's proposed expansion into the dental sector.

3. The company has announced the closure of its trading window for insiders from October 1, until 48 hours after the announcement of the financial results for the half-year ending September 30, in compliance with SEBI regulations.

Management Commentary

Navdeep Mehta, Managing Director of Novateor Research Laboratories Limited, stated, "The proposed expansion into dental equipment and chemicals trading represents a strategic move to diversify our business portfolio. We believe these new ventures will complement our existing operations and create new growth opportunities for the company."

The outcome of the shareholder vote on these proposed amendments will be crucial in determining the future direction of Novateor Research Laboratories Limited. Investors and stakeholders are advised to monitor further announcements from the company regarding the results of the AGM and the implementation of these proposed changes.

Novateor Research Laboratories Limited, a company listed on the Bombay Stock Exchange (BSE: 542771), has announced the appointment of Mr. Anil Tilakraj Arora as a Non-Executive Independent Director. The appointment, effective from September 3, 2025, was approved by shareholders at the company's 14th Annual General Meeting (AGM) held on September 30, 2025.

Appointment Details

Mr. Arora, who brings over four decades of experience as a dental practitioner and entrepreneur, has been appointed for a five-year term. His position will not be subject to retirement by rotation, in accordance with the provisions of sections 149 and 152 of the Companies Act, 2013.

Extensive Dental Expertise

With a career spanning more than 40 years, Mr. Arora has been a pioneer in India's dental community. His notable achievements include:

• Introducing India's largest private dental magazine
• Hosting the largest private dental exhibitions
• Running the largest network of private dental workshops

Mr. Arora's expertise extends to international dental conferences and involvement with boards of dental companies, making him a valuable addition to Novateor Research Laboratories' leadership.

Board Independence

The company has disclosed that Mr. Arora has no relationships with other board members, ensuring his independence in the role. This appointment aligns with corporate governance best practices, which emphasize the importance of independent oversight.

AGM Proceedings

The appointment was one of several items addressed during Novateor's AGM. Other key points from the meeting included:

• Adoption of financial statements for the year ended March 31, 2025
• Reappointment of Mr. Jitin Jaysukh Doshi as a director
• Authorization for related party transactions
• Approval for additions to the company's Memorandum of Association

Trading Window Closure

Following the AGM, Novateor Research Laboratories has announced the closure of its trading window for insiders, effective October 1, 2025. The window will reopen 48 hours after the announcement of the financial results for the half-year ending September 30, 2025.

This strategic appointment and the decisions made at the AGM reflect Novateor Research Laboratories' commitment to strengthening its governance and leveraging industry expertise to drive future growth in the dental and research sectors.